Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Intravitreal dexamethasone implant 0.7 mg vs sham

Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes

Intravitreal dexamethasone implant 0.7 mg showed no clear difference in gain of three or more lines visual acuity ‐ 12 months compared with sham (moderate certainty).

1 finding from 1 review

Intravitreal steroids for macular edema in diabetes 2020 · Cochrane Headline outcomes only
RR 1.39 [0.91, 2.12]
1 study · 701 participants
Moderate

Intravitreal dexamethasone implant 0.7 mg vs antiVEGF

Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes

Intravitreal dexamethasone implant 0.7 mg may leads to lower gain of three or more lines visual acuity ‐ 12 months compared with intravitreal antiVEGF (low certainty).

1 finding from 1 review

Intravitreal steroids for macular edema in diabetes 2020 · Cochrane Headline outcomes only
RR 0.99
Studies not reported
Low

Intravitreal fluocinolone acetonide implant 0.19 mg vs sham

Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes

Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher gain of three or more lines visual acuity ‐ 12 months compared with sham (moderate certainty).

1 finding from 1 review

Intravitreal steroids for macular edema in diabetes 2020 · Cochrane Headline outcomes only
RR 1.79 [1.16, 2.78]
1 study · 560 participants
Moderate